Bobby Sheng
Chairman

Mr. Sheng serves as Chairman since September 1, 2022 when the company and its subsidiaries joins Bora Group. Mr. Sheng is also the Group CEO & Chairman of Bora Group. Mr. Sheng received his Bachelor degree in Economics from University of California, Berkeley.

   Nick Liu
   President

Mr. Nick Liu has joined the Company since 2017 and assumed the responsibilities for corporate strategy, business development, and coordination among all the resources to support R&D development and business expansion. By leveraging his extensive experience of industry expertise and financial management, Mr. Liu is devoted to successfully delivering the growth potentials from TWi's extensive R&D pipeline as well as aggressively diversifying the portfolio with combined efforts from internal intelligence and external strategic partners. Mr. Liu received his MBA degree from University of Washington.

   Rick Pallokat
   President of US Commercial Operations

Mr. Rick Pallokat is responsible for TWi US operations. He brings in more than 25 years of sales and marketing experience in the Pharmaceutical industry and has great track records in his generic business career. Prior to joining TWi, Rick worked for Zenith Goldline, Andrx, and most recently DAVA. During his time with DAVA, Rick held various positions, including Sales VP, Operations VP, and Senior VP. He led and managed market development, product sales, supply chain, product pricing, and marketing strategies. He built the sales and marketing team that launched the first generic product for DAVA and accomplished significant business results. Mr. Rick Pallokat graduated from University of Fairleigh Dickinson and received his MBA degree in Marketing.

   David Chou
   Vice President of Production & Technical Service

Mr. David Chou has more than 28 years of manufacturing and management experience for GMP pharmaceutical factory. Prior to joining TWi, David served for Center Laboratories, INC., Canadian Pharmaceutical Laboratories (Pacific) Ltd. and St. Shine Optical Co., Ltd. He was dedicated to process improvement, scaling up and cost control. David joined TWi in 2004 and is in charge of manufacturing, including oral solid, oral liquid/suspension and semisolid product lines. He has successfully led TWi Chungli -Plant to pass US/FDA inspections for 3 times and commercial production of 4 ANDA products to US market. David received his B.S. degree of Pharmacy from Pharmacy department of Taipei Medical University.